Screener / SEC EDGAR /CIK 0001521036 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

Lantheus Holdings, Inc. LNTH

Compare with peers Embed
The 10-K against last year's

296 changes: 74 added, 48 removed, 170 reworded, 4 quiet changes

10-K Feb 26, 2026 vs Feb 26, 2025

10-K 0001193125-26-073498 (Feb 26, 2026) vs 10-K 0001628280-25-007970 (Feb 26, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

248 paragraphs · 37 new · 96 reworded · 21 gone · 10-K Feb 26, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 5 · 50% changed Every version of it
and government facilities no assurances that we serve. Any delay will be successful in those efforts or inability to enter into these arrangements, including our ability to negotiate favorable financial terms in these agreements, or if, despite favorable financial terms, that the customers do availability of TPT Status for other diagnostic radiopharmaceuticals will not continue to purchase PYLARIFY, impact clinical decision making regarding which product to use for all patient populations, which could have an adverse impact effect on our business, results of operations, financial condition and cash flows.
Paragraph 116 · 49% changed Every version of it
The field of diagnostic medical imaging market is dynamic, with new products, including highly dynamic. New imaging agents, equipment, software software, and products, diagnostic modalities are continually being developed developed, and existing products continually being refined. technologies are frequently refined or displaced. Our own diagnostic imaging agents compete not only with other similarly administered imaging agents agents, but also with imaging agents employed used in different and often alternative or competing diagnostic modalities. New hardware, software Advances in technology, shifts in clinical preferences, changes in perceptions regarding comparative efficacy, safety, or products in a given diagnostic modality may be developed that provide benefits superior to the then-dominant hardware, software and products in that modality, resulting in commercial displacement of the products. Similarly, changing perceptions about comparative efficacy and safety including, among other things, comparative radiation exposure, as well as changing availability of supply or changes in reimbursement methodologies or supplemental payments (including the availability of additional payments for new devices, such as granting of or loss of TPT Status, Status or reimbursement at ASP versus MUC) may favor one product over another competing products or one modality over another. modalities and reduce demand for our products. In addition, new or revised appropriate use criteria developed issued by professional societies, to assist physicians societies may reduce utilization of certain imaging procedures or agents. The development, timing, and other health care providers adoption of disease‑modifying therapeutics that require or are used in making connection with diagnostic imaging decisions for specific clinical conditions, can and have reduced the frequency of and may also affect demand for certain imaging modalities and imaging agents. To the extent there is technological obsolescence in our products. If any of our products, resulting products become technologically obsolete or are displaced by superior alternatives, we may experience reduced sales volumes or pricing pressure. Lower unit volumes could result in lower unit sales or decreased unit sales prices, we will have increased unit higher per‑unit overhead allocable to the remaining market share, costs, which could have a material adverse effect on materially adversely affect our business, results of operations, financial condition condition, and cash flows. Similar risks could apply to therapeutic products, including products we are developing.
Paragraph 12 · 49% changed Every version of it
Potential generic competitors may seek to enter the market as a result of patent and regulatory exclusivity expirations expiration, including the expiry of NCE regulatory exclusivity for PYLARIFY in May 2026.
Paragraph 19 · 48% changed Every version of it
Because our Orange Book-listed composition of matter patent expired in June 2019, we may face generic DEFINITY challengers (see Part I, Item 1., “Business - Regulatory Matters - Hatch Waxman Act” of this Form 10-K). As of the date of filing of this Form 10-K we have not received any Notice of approval for such a generic applicant pursuant to the Hatch Waxman Act, but we can give no assurance that product is sought by a competitor, we will not receive a Notice in the future. If we were to receive any such Notice in the future, we would review the Notice, evaluate the strength of any potential patent infringement claims, claims and be prepared to challenge the applicant in a timely fashion, which would thereby trigger the stay of up to 30 months. We can give no assurance that we would have grounds to file fashion. As a general matter, patent infringement suit, that we would obtain the full 30-month stay, that we would be successful on the merits asserting that an applicant infringes our Orange Book-listed patent, or that we would be successful defending the validity of our Orange Book-listed patent in court or in a U.S. Patent and Trademark Office (“USPTO”) adversarial proceeding. Patent litigation is complex and can be protracted and expensive, so if we were to receive such a Notice and to challenge the an applicant, this could have a negative effect on our business, results of operations and financial condition.
Paragraph 170 · 47% changed Every version of it
Our use of artificial intelligence (“AI”) or other emerging technologies could have a material adverse effect on adversely affect our business, results of operations, financial conditions condition and cash flows.
Paragraph 14 · 44% changed Every version of it
The NCE-1 date for PYLARIFY is currently has six patents listed in the FDA’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations” (the Orange Book”), the last of which expires in 2037. PYLARIFY also holds a five-year new chemical entity (“NCE”) regulatory exclusivity, which expires on May 26, 2025. 2026. As described further under Part I, Item 1., “Business - Regulatory Matters-Hatch Waxman Act,” of this is the date after which Form 10-K, the FDA is allowed to accept an Abbreviated New Drug Application (“ANDA”) or 505(b)(2) applications application one year prior to the NCE expiration date under certain circumstances, specifically, from a generic challenger that include includes a “Paragraph IV” Certification against each of the six patents we have listed in the Orange Book. If a Paragraph IV certification, from generic challengers. If this happens, Certification is made, we could elect to pursue Hatch-Waxman litigation and trigger the 30-month stay described under Part I, Item 1., “Business - Intellectual Property Matters – Patent-related Aspects of Regulatory Matters,” of this Form 10-K, during which period the FDA would be prohibited from granting full approval to the challenger’s application until application. As of the date of filing of this Form 10-K, we have not received any notice of a Paragraph IV Certification, but we can give no assurance that we will not receive notice of a Paragraph IV Certification in the future. If an ANDA or 505(b)(2) applicant were to file prior to the expiration of our NCE regulatory exclusivity, and we were to timely sue pursuant to the 30-month Hatch-Waxman Act, then the automatic stay and/or of FDA approval could run until November 26, 2028, calculated as 30 months from the NCE expiration date (May 26, 2026), unless prior to such date the generic challenger successfully invalidates or proves non-infringement of all six Orange Book-listed patents or the lawsuit is otherwise settled. The earliest possible date for If litigation is ongoing in November 2028, then any generic launch would be at risk of the litigation determining that the generic challenger was infringing one or more of our patents. Patent litigation is complex and can be protracted and expensive, so if we were to receive such a generic notice and to challenge the applicant, this could have a negative effect on our business, results of PYLARIFY to launch is November of 2027. operations and financial condition.
Paragraph 112 · 44% changed Every version of it
Our business depends on our ability to effectively manage existing products, successfully introduce develop and launch new products and indications, generate actionable insights from data, and adapt to a changing technology rapid technological and medical practice landscape. changes.
Paragraph 111 · 43% changed Every version of it
Use of our radiopharmaceutical diagnostic products is dependent upon the availability of staff at imaging centers and hospitals and PET scanners in the market. Our Accordingly, our ability to continue to generate substantial revenue from PYLARIFY, grow PYLARIFY Neuraceq, and to successfully launch new PET diagnostic products, including MK-6240 the new formulation of our PSMA PET imaging agent, MK-6240, LNTH-2501 and NAV-4694, is dependent upon the availability of such staff at imaging centers and hospitals and PET scanners generally. generally and our ability to ensure on time availability of our products to meet user needs. If there are staff shortages among imaging centers or hospitals, or if PET scanner capacity becomes constrained, or we are unable to meet the expectations of these customers, that could have a material adverse effect on our business, results of operations, financial conditions and cash flows.

MD&A

161 paragraphs · 37 new · 85 reworded · 27 gone · 10-K Feb 26, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 29 · 50% changed
On June 15, 2024, we entered into an agreement with Radiopharm to acquire global, exclusive rights to two licensed preclinical assets for an upfront payment of $2.0 million (the “Radiopharm Asset Purchase”). We acquired global, exclusive rights to both a monoclonal antibody that targets LRRC15, a preclinical therapeutic candidate targeting osteosarcoma, as LNTH-2403, and a Trophoblast cell surface antigen 2 (“TROP2”)-targeted nanobody, antigen-2 targeted radiodiagnostic, which we refer to as LNTH-2404, each of which is a preclinical stage therapy. therapeutic candidate. LNTH-2403 is our pre-clinical therapeutic targeting LRRC15, which is strongly expressed in multiple malignancies, including head and neck, breast, lung, and pancreatic cancers. In connection with this acquisition, we are assuming assumed the underlying license agreements related to the two preclinical assets, together with their respective milestone and royalty payment obligations.
Paragraph 84 · 49% changed
General and administrative expenses increased $68.2 $81.4 million for the year ended December 31, 2024 2025, as compared to the prior year period. ended December 31, 2024. This was primarily driven by an increase the impact of the acquisitions of Evergreen in investment April 2025 and Life Molecular in technology, primarily July 2025, including increased professional fees and employee-related costs, such as stock-based compensation expense, in 2025 as compared to 2024. We also incurred additional litigation expenses in 2025 related to our implementation intellectual property matters. We also incurred costs in 2025 associated with the expected divestiture of a new enterprise resource planning system in 2024, higher stock compensation, increased employee-related costs, and higher professional fees primarily related the SPECT business through the impending sale to business development activity. SHINE, which was completed on January 1, 2026.
Paragraph 74 · 49% changed
We classify our revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology consists of PYLARIFY and historically included AZEDRA. In the first quarter of 2024, we discontinued the production of AZEDRA. Precision Diagnostics includes DEFINITY, TechneLite Neuraceq (which we acquired on July 21, 2025 as part of our acquisition of Life Molecular), and other diagnostic imaging products. products, and historically included TechneLite, which we sold to SHINE on January 1, 2026. Strategic Partnerships and Other Revenue primarily includes biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and includes revenue derived from the partnerships with pharmaceutical companies and academic institutions that use our commercial or investigational products in clinical trials as research use tools. This category of MK-6420 revenues also includes royalties and NAV-4694. other milestone payments received from our strategic partners that have commercialized products pursuant to license arrangements with us as well as CDMO revenue generated by Evergreen, which we acquired on April 1, 2025.
Paragraph 8 · 48% changed
During 2024, we executed on our strategy to evolve into a fully integrated radiopharmaceutical company, supported by our increasingly diversified portfolio and our targeted initiatives to expand our pipeline, commercial, development and manufacturing capabilities. Over the course of the year and into 2025, we announced multiple strategic transactions, which furthered shape and sharpen our goal to strategic focus on new high growth markets and expand and diversify our capabilities and development pipeline with complementary assets. within the radiopharmaceutical industry. A brief description of these transactions is summarized below.
Paragraph 51 · 45% changed
•Strategic Partnerships – Partnerships– We seek to monetize our assets through our Strategic Partnerships business, which includes biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically. For example, we licensed the commercialization rights for piflufolastat F-18 We have partnerships with pharmaceutical companies and academic institutions that use our commercial and investigational products in Europe to Curium, where it is now commercialized under the brand name PYLCLARI, and for flurpiridaz, which received FDA approval in 2024 under the brand name Flyrcado, to GE Healthcare Limited (“GE Healthcare”). clinical trials as research tools.
Paragraph 135 · 44% changed
Our other long-term liabilities in the consolidated balance sheet include the fair values of contingent consideration liabilities including contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013. We may be required to pay up to approximately $85.0 million related to the contingent consideration. sales. As of December 31, 2024, 2025, these contingent payments were not expected to be payable within twelve months due to the uncertainty around the timing of the future cash flows.
Paragraph 155 · 44% changed
We account for business combinations using the acquisition method of accounting. We recognize the assets acquired and liabilities assumed in business combinations on the basis of their fair values at the date of acquisition. We assess the fair value of assets acquired, including intangible assets, and liabilities assumed using a variety of methods. Each asset acquired and liability assumed is measured at fair value from the perspective of a market participant. The method used to estimate the fair values of intangible assets incorporates significant assumptions regarding the estimates a market participant would make in order to evaluate an asset, including a market participant’s use of the asset and the appropriate discount rates. Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. Any excess purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. Transaction costs and restructuring costs associated with a business combination are expensed as incurred.
Paragraph 97 · 43% changed
Net cash provided by used in investing activities during the year ended December 31, 2023 2025 was primarily due driven by $268.9 million paid to net cash proceeds the former holders of $97.8 million from Evergreen Shares for the sale of our RELISTOR royalty asset offset by $45.3 million for our asset acquisition of Cerveau Evergreen, net of cash acquired, $306.7 million paid for the acquisition of Life Molecular net of cash acquired, $10.0 million used to purchase equity securities, $5.4 million of milestone payments related to RM2 made in 2025 and $46.6 $36.1 million of capital expenditures.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors304 words changed in this paragraph; it is 65% similar to last year's version.
Ensuring adequate coding, coverage, and payment for PYLARIFY is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using PYLARIFY in PET/computed tomography (“CT”) imaging procedures. The Healthcare Procedure Coding System code for PYLARIFY, which enables streamlined billing, went into effect as of January 1, 2022. PYLARIFY also had TPT Status from January 1, 2022 until December 31, 2024, which enabled traditional Medicare to provide an incremental payment for PET/CT scans performed with PYLARIFY in the hospital outpatient setting until December 31, 2024. Historically, after setting. After expiry of TPT Status expired, Status, diagnostic radiopharmaceuticals, such as, PYLARIFY, historically would not have been separately reimbursed in the hospital outpatient setting but rather would be bundled into the facility payment a hospital receives for a PET/CT imaging procedure, and the facility payment may not have adequately covered the total cost of the procedure with the diagnostic radiopharmaceutical for all hospitals. In November 2024, CMS the Centers for Medicare & Medicaid Services (“CMS”) released the final rule for its calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (the “CMS 2025 OPPS Rule”). Under the new rule, The CMS 2025 OPPS Rule became effective on January 1, 2025, pursuant to which previously packaged diagnostic radiopharmaceuticals are now were “unbundled” with payments being made separately for any diagnostic radiopharmaceutical with a per day cost greater than $630 based on the their mean unit cost (“MUC”). For approximately 20% of traditional In November 2025, CMS released the final rule for its calendar year 2026 Medicare fee-for-service (“FFS”) patients in the hospital outpatient setting, Hospital Outpatient Prospective Payment System, which continues to provide for separate payment for diagnostic radiopharmaceuticals with per day costs greater than $655 based on their MUC. While these changes enable hospitals that use innovative diagnostic radiopharmaceuticals, including PYLARIFY, to continue to be paid separately by CMS following the expiry of TPT Status Status, that payment is made at a rate that reflects MUC. The calendar year 2025 As a result, as of January 1, 2025, the payment rate for PYLARIFY is based on MUC and is less than the Average Sales Price (“ASP”)-based amount that was paid during TPT Status. Although PYLARIFY continues to be paid separately, other competitive PSMA PET imaging agents continue to have TPT Status after December 31, 2024 2024, including a new PSMA PET imaging agent with TPT Status effective on October 1, 2025, and hospital use of those products, for the approximately 20% of patients with traditional Medicare FFS patients fee-for-service (“FFS”) in the hospital outpatient setting, generally will be paid separately based on ASP plus six percent rather than on MUC. MUC, which provides a financial incentive to use an imaging agent other than PYLARIFY. We have reported and continue to report ASP for PYLARIFY, have engaged with CMS on the methodology for reporting ASP, and we will continue to work with coalition partners and CMS to support using ASP rather than MUC to calculate payment for diagnostic radiopharmaceuticals in future years similar to the way Medicare Outpatient Prospective Payment System (“OPPS”) currently pays for other drugs, biologics, and therapeutic radiopharmaceuticals. However, we can give no assurances that we will be successful in those efforts or that the availability of TPT Status for other diagnostic radiopharmaceuticals will not impact clinical decision making regarding which product to use for all patient populations, which could have an adverse effect on our business, results of operations, financial condition and cash flows.

Source: Item 1A, 10-K 0001193125-26-073498 vs Item 1A, 10-K 0001628280-25-007970

Accounting Policies238 words changed in this paragraph; it is 35% similar to last year's version.
In November 2024, the FASB issued ASU 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40),” and in January July 2025, the FASB issued ASU 2025-01, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying 2025-05, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets,” which provides a practical expedient related to the Effective Date.” estimation of expected credit losses for accounts receivable and current contract assets that arise from transactions accounted for under ASC 606, “Revenue Recognition.” ASU 2024-03 2025-05 requires additional income statement disclosures, including an entity to disclose whether it has elected to use the disaggregation of specific categories of expenses underlying practical expedient. An entity that makes the line items presented on accounting policy election is required to disclose the income statement. Additionally, ASU 2024-03 requires enhanced disclosure of selling expenses. As clarified by ASU 2025-01, the date through which subsequent cash collections are evaluated. The requirements of the guidance ASU 2025-05 are effective for annual periods beginning after December 15, 2026 2025, and interim periods within fiscal years beginning after December 15, 2027. For the Company, annual reporting requirements under ASU 2024-03 will be effective for its Annual Report on Form 10-K for the year ending December 31, 2027 and interim reporting requirements will be effective beginning in the first quarter of 2028. 2026. Early adoption is permitted in both interim and the amendments should be applied on a prospective basis, however retrospective application is permitted. annual reporting periods in which financial statements have not yet been issued or made available for issuance. The Company is currently in the process of evaluating the effects of this pronouncement and believes that the adoption will not have a material impact on our its consolidated financial results statements and related disclosures.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001193125-26-073498 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001628280-25-007970

MD&A170 words changed in this paragraph; it is 52% similar to last year's version.
In November 2024, On July 31, 2025, our Board authorized a program to repurchase up to $400.0 million of shares of our common stock through December 31, 2027 (the “2025 Program”). The 2025 Program replaced the program authorized by the Board in November 2024 to repurchase up to $250 million of our common stock during the next twelve months following the authorization (the “2024 Program”). Such repurchases may be made Program”), including the remaining unused amounts under the 2024 Program. We repurchased 1.3 million shares for approximately $100.0 million under the 2024 Program in 2025. The 2025 Program authorizes us to purchase shares of our common stock from time to time via open market purchases at prevailing market prices, in privately negotiated transactions, block trades, or pursuant to trades intending to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The actual timing, number manner, price and dollar amount of any repurchase transactions will be determined by our management, in its subject to the discretion and will depend on a number of factors, including but not limited to, the market price of our Management. The 2025 Program does not obligate us to acquire any particular amount of its common stock. As of December 31, 2024, cumulative shares purchased under stock, and we may suspend or discontinue the 2024 2025 Program were approximately 1.1 at any time. We repurchased 3.5 million shares for approximately $100.0 million. $200.0 million under the 2025 Program in 2025.

Source: Item 7, 10-K 0001193125-26-073498 vs Item 7, 10-K 0001628280-25-007970

Legal Proceedings49 words changed in this paragraph; it is 78% similar to last year's version.
As of December 31, 2024, the Company did not have any material ongoing litigation to which the Company was a party. On January 26, 2024, the Company was sued in the United States District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the filing of our Abbreviated New Drug Application and Paragraph IV certification in connection with PNT2003, consistent with the process established by the Hatch-Waxman Act. In December 2025, the court conducted its trial. As of the date of this Form 10-K, the Company is currently waiting for the court to issue its decision. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved.

Source: Item 3, via Note 17 – Commitments and Contingencies, 10-K 0001193125-26-073498 vs Item 3, via Note 19 – Commitments and Contingencies, 10-K 0001628280-25-007970

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of LNTH's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 26, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Following the expiration of regulatory exclusivity, we may face increased competition from generic products, including through abbreviated approval pathways under the Hatch‑Waxman Act or as a result of actions brought under the CREATES Act. The likelihood of entry or anticipated entry of such competing products cannot be predicted and could significantly reduce demand for our products, pressure pricing and reimbursement, and adversely affect our business, results of operations, and financial condition.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our ability to grow Neuraceq is dependent on (A) our ability to engage our existing PYLARIFY customers to introduce Neuraceq to those customers, (B) expanded geographical access to Neuraceq, which in turn depends on our ability to increase Neuraceq manufacturing capacity at existing manufacturing sites and add additional sites, (C) increased adoption and utilization of beta-amyloid PET and anti-amyloid therapeutics, (D) increased utilization based on the updated Neuraceq prescribing information indicating that Neuraceq can be used for patient selection for anti-amyloid therapies where the prescribing information for the therapy so states, (E) our ability to educate customers on the approved uses of Neuraceq, including its ability to quantify the degree of amyloid burden in the brain and (F) our ability to clinically differentiate Neuraceq from competitive products so that customers choose Neuraceq for appropriate patients because of its clinical attributes and despite the disparity in MUC payment rates for Neuraceq compared to other products used for traditional Medicare patients in the hospital outpatient setting.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Ensuring adequate coding, coverage, and payment for Neuraceq is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using Neuraceq in PET/ CT imaging procedures. Neuraceq was approved by the FDA in 2014. When used for traditional Medicare patients in the hospital outpatient setting, Neuraceq is paid based on its MUC; however, Neuraceq currently competes with two commercially available F-18 beta-amyloid-targeting PET imaging agents from Eli Lilly and Co (“Lilly”) and GE Healthcare, and those other competitive imaging agents are currently being paid based on a higher MUC rate. While we have engaged with CMS to support the use of ASP instead of MUC, we can give no assurances that CMS will move to the use of ASP in the near term or that the availability of a higher MUC payment rate for other diagnostic radiopharmaceuticals will not continue to impact clinical decision making regarding which product to use for all patient populations, which could have an adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
In addition, growth and revenue contribution from Neuraceq will also depend on our ability to clinically differentiate Neuraceq from competitive products and to educate customers on the approved uses of Neuraceq, including its ability to quantify the degree of amyloid burden in the brain so that customers choose Neuraceq for appropriate patients because of its clinical attributes and despite the disparity in MUC payment rates for Neuraceq compared to other products used for traditional Medicare patients in the hospital outpatient setting. Further, certain currently approved therapeutic products in the United States require confirmation of the presence of amyloid beta pathology prior to initiating treatment. If this requirement in the prescribing information for these products were to change it could have an adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•For DEFINITY, our competitors currently include GE Healthcare and Bracco, as well as echocardiography without ultrasound enhancing agents and other non-echocardiography agents, and there is the potential for future competition from generic manufacturers who may submit regulatory applications using DEFINITY as the reference listed drug (RLD).
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
In addition, in order to remain competitive, in certain circumstances, we provide customers with rebates, which we estimate as a reduction to revenue at the time revenue is recognized. Judgment is required in making these estimates. These rebates can include performance-based offers that are based on attaining contractually specified sales volumes, Medicaid rebate programs for our products, administrative fees of group purchasing organizations and certain distributor-related commissions. The calculation of the accrual for these rebates is based on an estimate of the third-party’s expected purchases and the resulting applicable contractual rebate to be earned over a contractual period and our estimates can vary by program, product, type of customer and geographic location. In determining the appropriate accrual amount, we consider the contractual terms, historical sales, and changes in sales trends. Specific rebates can impact year-over-year individual product revenue growth trends. If any of our assessments, assumptions, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be impacted.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
The full impact on our business of healthcare reforms and other new laws, or changes in existing laws, the interpretations of those laws, or changes to the way regulations and regulatory guidance has been implemented, amended and interpreted, is uncertain. Nor is it clear whether additional legislative or executive branch changes will be adopted or how those changes would affect our industry in general or our ability to successfully commercialize our products or develop or commercialize new products. For example, recent government actions, including reductions in staff and department reorganizations, including those at the FDA, could adversely affect the timing of anticipated regulatory actions or their outcome, and could change historical practices relating to the application or interpretation of regulations relevant to our operations in ways that could have an adverse effect on our business. It is unclear exactly how changes implemented by the U.S. government will affect the U.S. healthcare system, and what impact this will have on our business. If the reforms made by the OBBBA are implemented and result in predicted coverage losses, these changes could reduce the overall number of diagnostic medical imaging procedures performed, reduce reimbursement rates, or both. Additionally, changes in U.S. drug pricing policies, including initiatives that seek to link domestic prices to those paid in other countries under “most‑favored‑nation” pricing concepts, could increase pricing pressure on our products. Any such policies, if implemented or expanded, could reduce reimbursement levels, constrain pricing flexibility, and adversely affect our revenues and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 68
AddedRisk Factors
For additional information regarding risk associated with legal proceedings other than those related to intellectual property, See “Our business and operations could be negatively affected by any pending or future securities litigation.”
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Competition in our industry for highly skilled scientific, healthcare and sales personnel is intense and we may compete with larger pharmaceutical companies that likely will have access to greater financial resources than we do. As we expand our product
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Our success is substantially dependent upon the performance, contributions and expertise of our executive leadership, senior management team and other key personnel. Our executive leadership, senior management team and other key personnel play a significant role in formulating and executing on our long-term strategy, generating business and overseeing operations. We have experienced, and may continue to experience, significant executive management changes, including the consolidation of roles and responsibilities. Brian Markison, our former Chief Executive Officer (“CEO”), retired from the Company effective December 31, 2025, and Mary Anne Heino, the Chair of our Board of Directors, is serving as our CEO as of January 1, 2026 while the Board of Directors conducts a comprehensive search for our next CEO. Our former President, Paul Blanchfield, accepted a role with another company and left the Company in November 2025. We also have experienced and may continue to experience the departure and transition of other members of the leadership team.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
Obtaining adequate coding, coverage, and payment for PYLARIFY is critical, including not only coverage from Medicare, Medicaid and other government payors, as well as private payors, but also appropriate payment levels to adequately cover our customers’ costs of using PYLARIFY in PET/computed tomography (“CT”) imaging procedures. The Healthcare Procedure Coding System code for PYLARIFY, which enables streamlined billing, went into effect as of January 1, 2022. In addition, effective January 1, 2022, the Centers for Medicare and Medicaid Services (“CMS”) granted TPT Status for PYLARIFY, enabling traditional Medicare
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
A critical ingredient of TechneLite is Mo-99. We currently purchase finished Mo-99 from three of the four main processing sites in the world, namely Institute for Radioelements (“IRE”) in Belgium, NTP Radioisotopes (“NTP”) in South Africa and Australian Nuclear Science and Technology Organisation (“ANSTO”) in Australia. These processing sites provide us Mo-99 from five of the six main Mo-99-producing reactors in the world, namely BR2 in Belgium, LVR-15 in the Czech Republic, HFR in The Netherlands, SAFARI in South Africa and OPAL in Australia.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Although we have a globally diverse Mo-99 supply with IRE in Belgium, NTP in South Africa, and ANSTO in Australia, we still face supplier and logistical challenges in our Mo-99 supply chain. When one supplier experiences outages, we generally rely on Mo-99 supply from the other suppliers to limit the impact of the outages. We believe we effectively manage these various supply chain challenges, but depending on reactor and processor schedules and operations, at times we have not been able to fill some or all of the demand for our TechneLite generators on certain manufacturing days. A prolonged disruption of service from one of our three Mo-99 processing sites or one of their main Mo-99-producing reactors could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
U.S., Canadian and international governments have encouraged the development of a number of alternative Mo-99 production projects with existing reactors and technologies as well as new technologies. However, we cannot say when, or if, the Mo-99 produced from these projects will become available. As a result, there is a limited amount of Mo-99 available which could limit the quantity of TechneLite that we could manufacture, sell and distribute, resulting in a substantial negative effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Most of the global suppliers of Mo-99 rely on Framatone-CERCA in France to fabricate uranium targets and in some cases fuel for research reactors from which Mo-99 is produced. Absent a new supplier, a supply disruption relating to uranium targets or fuel could have a substantial negative effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
DEFINITY is an ultrasound enhancing agent based on perflutren lipid microspheres. In 2007, the FDA received reports of deaths and serious cardiopulmonary reactions following the administration of ultrasound enhancing agents used in echocardiography. Four of the 11 reported deaths were caused by cardiac arrest occurring either during or within 30 minutes following the administration of the ultrasound enhancing agent; most of the serious but non-fatal reactions also occurred in this time frame. As a result, in October 2007,
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
The full impact on our business of healthcare reforms and other new laws, or changes in existing laws, is uncertain. Nor is it clear whether additional legislative changes will be adopted or how those changes would affect our industry in general or our ability to successfully commercialize our products or develop or commercialize new products. It is also unclear exactly how the results of the 2024 election will impact healthcare reform measures of the previous administration or whether the new administration could impose other reform efforts, including what, if any, impact this will have on our business.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Similarly, in June of 2024, Endocyte, Inc. (“Endocyte”), Novartis and Purdue Research Foundation sued POINT Biopharma Global Inc. (“POINT”) and Lilly alleging that POINT’s manufacturing and sale of PNT2002 infringes an Endocyte patent that discloses PSMA-binding conjugates useful for delivery targeted therapeutic, diagnostic and imaging agents, including radiopharmaceuticals. While we have not been named as a party to the lawsuit, if POINT is found to be infringing on proprietary rights of Endocyte, it could prevent or result in a delay in our development and commercialization of PNT2002 or otherwise have an adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
The healthcare industry is characterized by continuous technological development resulting in changing customer preferences and requirements. The success of new product development depends on many factors, including our ability to fund development of new products or new indications for existing products, anticipate and satisfy customer needs, obtain timely regulatory approval based on performance of our products in development versus their clinical trial comparators, develop and manufacture products in a cost-effective and timely manner, maintain advantageous positions with respect to intellectual property and differentiate our products from our competitors. To compete successfully in the marketplace, we must make substantial investments in new product development, whether internally or externally through licensing or acquisitions. Our failure to introduce new and innovative products in a timely manner would have an adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
Even if we are able to develop, manufacture and obtain regulatory approvals for our new products, the success of these products would depend upon market acceptance and adequate coding, coverage and payment. Levels of market acceptance for our new products could be affected by a number of factors, including:
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedRisk Factors
Although PYLARIFY is broadly available across the U.S., we We also continue to seek qualification for additional PMFs in 2025 2026 and we can give no assurance that additional PMF sites will have the capacity to produce Neuraceq in addition to other products they may already produce, including other F-18-based products, that those PMF sites will be willing to commit to manufacture Neuraceq and successfully complete the technology transfer process necessary to manufacture Neuraceq, that the FDA will continue to approve PMFs in accordance with our expansion plans to meet increasing product demand or that PYLARIFY Neuraceq will always be available at the specific time of day preferred by the end-users. end-users or that our expansion plans accurately predict demand growth.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Although PYLARIFY is broadly available across the U.S., United States, we will continue to seek qualification for additional PMFs in 2025 2026 and can give no assurance that additional PMF sites will have the capacity to produce PYLARIFY in addition to other products they may already produce, including other F-18-based products, that those PMF sites will be willing to commit to manufacture PYLARIFY and successfully complete the technology transfer process necessary to manufacture PYLARIFY, that the FDA will continue to approve PMFs in accordance with our expansion plans to meet increasing demand or product demand, that PYLARIFY will always be available at the specific time of day preferred by the end-users. end-users or that our expansion plans accurately predict demand growth.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We cannot anticipate the actions of our current or future competitors in the same or competing modalities, such as significant price reductions on products that are competitive with our own, the ability to offer a portfolio of products and offer price reductions across a portfolio, development of new products that are more cost-effective or have superior performance or higher reimbursement than our current products or products, potential future products or the introduction of generic versions of our proprietary products. products, the ability to secure better manufacturing locations or times for production of current or future products that limit the availability of necessary raw materials, production equipment, components or radiopharmacist time or, for our diagnostic agents, PET scanner capacity.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We may be limited in our ability to use these tax loss carryforwards to reduce our future U.S. federal and state income tax liabilities if our future income is not sufficient to absorb the losses, or if we were to experience another “ownership change” as specified in Section 382 of the Internal Revenue Code including if we were to issue a certain amount of equity securities, certain of our stockholders were to sell shares of our common stock, or we were to enter into certain strategic transactions. losses.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Although we have qualified and continue to qualify additional PMFs, we can give no assurance that additional PMF sites will have the capacity to produce PYLARIFY and Neuraceq in addition to other products they may already produce, including other F-18-based products, that those PMF sites will be willing to commit to manufacture PYLARIFY and Neuraceq and successfully complete the technology transfer process necessary to manufacture PYLARIFY and Neuraceq, that the FDA will continue to approve PMFs in accordance with our planned roll-out schedule or that the PMFs will not experience issues with their ability to manufacture and deliver PYLARIFY or Neuraceq to our customers.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In 2024, October 2025, we held a pre-NDA meeting with announced that the FDA and we expect to submit a new drug application (“NDA”) had accepted our NDA for MK-6240 in 2025, and has set a PDUFA target action date of August 13, 2026, but we can provide no assurance that we will meet that expected timeline, that our NDA will be accepted by the FDA, that MK-6240 will be approved by the FDA based on the data submitted or, if approved, that we will be successful in commercializing MK-6240.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In November 2024, July 2025, our Board of Directors (the “Board”) authorized a program to repurchase up to $250.0 $400.0 million over the next twelve months of shares of our common stock through December 31, 2027, via open market purchases or purchases, privately negotiated transactions, block trades and/or or pursuant to trades intending to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations (the “2024 “2025 Program”).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
As described further under Part I, Item 1., “Business - Regulatory Matters-Hatch Waxman Act,” of this is the date after which Form 10-K, the FDA is allowed to accept an Abbreviated New Drug Application (“ANDA”) or 505(b)(2) applications application one year prior to the NCE expiration date under certain circumstances, specifically, from a generic challenger that include includes a Paragraph IV certification, from generic challengers. “Paragraph IV” Certification against each of the six patents we have listed in the Orange Book.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If production capacity is not available, FDA approval of manufacturing sites is delayed or withdrawn or if withdrawn, FDA requirements relating to site approval change, change in a way that impacts our ability to meet demand for Neuraceq or end users scheduling needs or if we invest to extend our PMF network and demand does not grow to meet the expanded capacity, our business, results of operations, financial condition and cash flows could would be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Our Accordingly, our ability to continue to generate substantial revenue from PYLARIFY, grow PYLARIFY Neuraceq, and to successfully launch new PET diagnostic products, including MK-6240 the new formulation of our PSMA PET imaging agent, MK-6240, LNTH-2501 and NAV-4694, is dependent upon the availability of such staff at imaging centers and hospitals and PET scanners generally. generally and our ability to ensure on time availability of our products to meet user needs.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Our ability to continue to grow Continued substantial revenue contribution from PYLARIFY as a commercial product is dependent on (A) the ability of positron emission tomography (“PET”) manufacturing facilities (“PMFs”) to manufacture PYLARIFY to meet product demand or demand, including ensuring that PYLARIFY will always be is available at the specific time of day preferred by the end-user, (B) our ability to maintain ensure adequate coding, coverage and payment for PYLARIFY, (C) our ability to promote PYLARIFY to customers and to maintain PYLARIFY as the most a widely utilized prostate-specific membrane antigen (“PSMA”) PET imaging agent, including after which has been impacted by the expiration of transitional pass-through payment status (“TPT Status”) at the end of on December 31, 2024, (D) whether and when a potential generic version of PYLARIFY may enter the market and (E) our ability to clinically and commercially differentiate PYLARIFY from other competitive products.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Continued growth and Substantial revenue contribution from PYLARIFY will also depend on our ability to clinically differentiate PYLARIFY in light from competitive products so that customers continue to choose PSMA PET with PYLARIFY for appropriate patients because of its clinical differentiation and despite the loss of TPT Status, including through flexible and dependable access to PYLARIFY nationally, a best-in-class customer experience and through long-term strategic contracts. continued promotion and education regarding PYLARIFY’s clinical and commercial attributes.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
While we have experienced some turnover on our executive leadership team, we have generally been able to fill positions by either promoting existing employees or attracting new, qualified individuals to lead key functional areas.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
To obtain regulatory approval for these products, we must may need to conduct extensive human tests, which are referred to as clinical trials, as well as meet other rigorous regulatory requirements, as further described in Part I, Item 1.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
If However, if such a right becomes available again and if one or more holders elect to convert their Notes, unless we elect to satisfy our conversion obligation by arranging for one or more financial institutions to take the Notes from converting holders and pay such holders in accordance with the Indenture, we would be required to settle any converted principal amount of such Notes through the payment of cash and by paying or delivering, at our election, cash, shares of our common stock, or a combination of cash and shares, with respect to the remainder of our conversion obligation in excess of the aggregate principal amount of the Notes being converted, which could adversely affect our liquidity or, if we elect to settle our conversion obligation in excess of the aggregate principal amount of the Notes being converted in shares of common stock (whether in whole or in part), could dilute the ownership interests of our existing common stockholders.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
Our stock price could fluctuate has fluctuated significantly, which could cause the value of your investment in our common stock to decline, and you may not be able to resell your shares at or above your purchase price.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On January 1, 2026, we completed the sale of our single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. We are entitled to receive total consideration of up to $155.0 million, consisting of cash, a convertible installment note, a term note and contingent earnout payments. Under the terms of the definitive agreement, SHINE acquired the assets and liabilities associated with our SPECT business, including its approved products (TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite), the portion of the North Billerica, Massachusetts campus that manufactured our SPECT products and the SPECT-related Canadian operations. The transaction allows us to focus on growing our commercial portfolio of innovative PET radiodiagnostics and microbubbles, while advancing our pipeline of radiopharmaceuticals.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Effective November 7, 2025, Mary Anne Heino, the Chair of our Board of Directors (the “Board”), was appointed to serve as our Executive Chair and principal executive officer. Additionally, on January 1, 2026 (the “Effective Date”), Ms. Heino became our Chief Executive Officer (“CEO”), following the retirement of our former CEO, Brian Markison on December 31, 2025. Ms. Heino will serve as CEO until such time as the Board completes the comprehensive search process that it initiated to
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In October 2025, we announced that the FDA has set a PDUFA target action date of March 29, 2026 for LNTH-2501. LNTH-2501 is a diagnostic kit for the preparation of Gallium-68 (“Ga-68”) edotreotide injection, which has been studied for use with PET imaging for localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In October 2025, we announced that the FDA had accepted our New Drug Application (“NDA”) for MK-6240, our registrational F-18 tau-targeted PET imaging agent for the detection of tau neurofibrillary tangle pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease, and has set a PDUFA target action date of August 13, 2026. During the second quarter of 2025, we announced that MK-6240 successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. The data from these two studies supported our NDA submission to the FDA. MK-6240 previously received Fast Track designation from the FDA for its potential to address an unmet medical need in Alzheimer’s disease diagnostics.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On September 24, 2025, we announced an exclusive licensing agreement for GE HealthCare Limited (“GE Healthcare”) to develop, manufacture, and commercialize Lantheus’ piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use. Under the terms of the agreement, GE Healthcare paid us an upfront license fee and will pay us development milestones and tiered royalties based on product sales in Japan.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In August 2025, we announced that the FDA had accepted our NDA for a new formulation of our F-18 PSMA PET imaging agent, filed by our subsidiary Aphelion, and that the FDA has set a PDUFA target action date of March 6, 2026. The new formulation was designed to enhance product stability and increase batch production, with the potential to enhance supply flexibility and improve operating leverage across the network. If the NDA is approved, we plan to work closely with clinicians and PMF sites to ensure a smooth rollout of the new formulation, including providing clear guidance on ordering, handling, and clinical use to support continuity of care for patients, and we plan to apply for reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for the new formulation, including seeking three years of TPT Status.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On July 21, 2025, we acquired Life Molecular, pursuant to the terms of the Sale and Purchase Agreement with Life Medical Group Limited (“Life Medical”) and Life Healthcare Group Holdings Limited (the “Sale and Purchase Agreement” and, such acquisition, the “LMI Acquisition”). Life Molecular, headquartered in Berlin, Germany, possesses an Alzheimer’s disease radiodiagnostic commercial infrastructure, research and development (“R&D”) capabilities, and an established international footprint. The LMI Acquisition includes Neuraceq, an Alzheimer’s disease radiodiagnostic. Neuraceq is commercially approved in the United States, Canada, the European Union, the United Kingdom, Switzerland, China, Japan, South Korea, and Taiwan.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
As consideration for the LMI Acquisition, we remitted an upfront payment of $355.2 million in cash, and could be required to pay up to an additional $400.0 million in potential earn-out and milestone payments. In November 2025 and in accordance with the terms of the Sale and Purchase Agreement, we finalized the net working capital accounts with Life Medical and we received a $2.3 million payment from Life Medical. This $2.3 million payment was recorded as an adjustment to purchase
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
consideration in the fourth quarter of 2025. Additionally, we assumed a contingent consideration liability owed to Piramal Holdings SA (“Piramal”), pursuant to a Securities Purchase Agreement between Piramal and Life Molecular.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In connection with the LMI Acquisition, the RM2 Sublicense Agreement was amended to (i) reduce the contingent regulatory and development milestones by €45.0 million; (ii) assign the right to future payments from Life Molecular to its former parent, Life Medical; and (iii) eliminate certain other non-substantive rights contained in the RM2 Sublicense Agreement (the “RM2 Amendment”). We determined that the RM2 Amendment did not constitute settlement of a pre-existing relationship in accordance with Accounting Standards Codification 805, “Business Combinations”, and concluded that the amendment represented a modification to the RM2 Sublicense Agreement, whereby we did not reacquire any incremental rights or assets. Accordingly, we will continue to account for the RM2 Sublicense Agreement as an asset acquisition, separate from the LMI Acquisition. We may be required to pay Life Medical additional milestone payments and royalties in connection with the RM2 Asset Purchase. GRPR is a member of the bombesin G protein-coupled receptor family, which has been found to be overexpressed in multiple cancers. First-in-human dosimetry showed a favorable safety and dosimetry profile and confirmed preclinical data demonstrating dose-dependent efficacy of LNTH-2402. We submitted investigational new drug applications in support of a Phase 1b/2 clinical trial with the LNTH-2401/LNTH-2402 theranostic pair in prostate cancer patients in the fourth quarter of 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
On January 13, 2025, we announced that we entered into a definitive agreement to acquire Life Molecular Imaging Ltd. (“Life Molecular”). Life Molecular is based in Berlin, Germany and is dedicated to advancing novel PET radiopharmaceutical diagnostics. The definitive agreement provides for an upfront payment of $350.0 million and up to an additional $400.0 million in potential earn-out and milestone payments. The transaction is expected to close in the second half of 2025, subject to the satisfaction of customary regulatory and closing conditions.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Pursuant to the Evergreen Merger Agreement, we will pay an upfront amount of $250 million, payable in cash at closing and subject to customary adjustments as set forth in the Evergreen Merger Agreement, and milestone payments in an aggregate additional cash amount of up to $752.5 million upon the occurrence of certain Milestone Trigger Events (as set forth in the Evergreen Merger Agreement). We also agreed to provide up to $18 million in unsecured loans to Evergreen on the terms set forth in the Merger Agreement. The Evergreen Merger is expected to close in the second half of 2025, subject to the satisfaction of customary regulatory and closing conditions.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On January 22, 2024, we purchased 56,342,355 shares of Perspective’s common stock (“Perspective Shares”) at a purchase price of $0.37 per share in a private placement transaction, for approximately $20.8 million in cash. We were also granted certain pro rata participation rights to maintain our ownership position in Perspective in the event that Perspective makes any public or non-public offering of any equity or voting securities, subject to certain exceptions.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On March 6, 2024, we purchased 60,431,039 Perspective Shares at a price of $0.95 per share. The total consideration for this additional purchase was approximately $57.4 million, resulting in Lantheus Alpha holding approximately 19.90% of the outstanding Perspective Shares (or 17.35% on a fully diluted basis) as of March 6, 2024.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On March 1, 2024, Brian Markison, our then Chair of our Board of Directors (the “Board”), became our Chief Executive Officer (“CEO”), and Mary Anne Heino, retired as our CEO and became the Chair of our Board. As part of this leadership transition, Mr. Markison assumed the role of Executive Chair of the Board as of January 23, 2024 until the effectiveness of his CEO appointment in March, and Board Member Julie McHugh became Lead Independent Director.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
As part of our evolution into a fully integrated radiopharmaceutical company, during 2024, we reviewed our current capabilities and skillsets and began implementing organizational changes deemed necessary to best position us to execute on our long-term strategy. These changes included transitioning approximately 60 employees out of the Company. In connection with these changes, we approved equity modifications that allowed grants of stock options and restricted stock units (“RSUs”) issued to those impacted by this event to continue to vest in 2024 and 2025 with any unvested stock option and RSU grants as of December 31, 2025 to be cancelled. Total stockholder return awards granted to these individuals will continue to vest on their original vesting schedule but any shares issued will be issued in a pro-rated amount based on the time served during the performance period.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
In September 2023, MK-6240 was granted Fast Track designation by the FDA. In February 2024, we announced the inclusion of MK-6240 in the National Institute on Aging-sponsored study called CLARiTI that enables the consortium to use MK-6240 in its investigation of Alzheimer’s disease and related dementias. The CLARiTI study will involve all 37 Alzheimer’s Disease Research Centers in the United States and will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
In 2024, we held a pre-NDA meeting with the U.S. Food and Drug Administration (“FDA”) and we expect to submit an NDA for MK-6240 in 2025, but we can provide no assurance that we will meet that expected timeline, that our NDA will be accepted by the FDA, that MK-6240 will be approved by the FDA or, if approved, that we will be successful in commercialization.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
On August 15, 2023, we announced that we would discontinue the production and promotion of AZEDRA and wind down our Somerset Facility. We continued manufacturing AZEDRA during the first quarter of 2024, to provide doses of AZEDRA to then-current patients so they could complete their treatment regimen. No AZEDRA was manufactured after March 1, 2024, when we transferred the assets and associated sublease of our Somerset Facility to Perspective.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Our Healthcare Procedure Coding System code, which enables streamlined billing, went into effect as of January 1, 2022. In addition, from January 1, 2022 to December 31, 2024, PYLARIFY had TPT Status from the Centers for Medicare and Medicaid Services (“CMS”) in the hospital outpatient setting, enabling traditional Medicare FFS to provide separate payment for PYLARIFY in addition to the payment for the PET/computed tomography (“CT”) procedure in that setting.
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedMD&A
Net cash provided by operating activities of $544.8 $390.1 million during the year ended December 31, 2024 2025 was primarily comprised of net income adjusted for the net effect of non-cash items such as unrealized loss on investment in equity securities, charges incurred in connection with the Perspective IPR&D exclusive license options, charges related to Radiopharm’s licensed assets, charges related to Life Molecular’s RM2 license, gains on disposal adjustments to the fair value of our Somerset Facility asset retirement obligation and a portion of our North Billerica, Massachusetts facility, contingent assets and liabilities, depreciation, amortization and accretion expense expense, deferred taxes and stock-based compensation expense.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
(“Evergreen”) On April 1, 2025, we acquired all the issued and Shareholder Representative Services LLC, pursuant to which we will acquire outstanding shares of Evergreen by means of a statutory merger of our subsidiary with and into Evergreen, with Evergreen surviving as our wholly-owned subsidiary (the “Evergreen Merger”). Merger”), pursuant to the terms of the Agreement and Plan of Merger (the “Evergreen Merger Agreement”) with Evergreen and Shareholder Representative Services LLC.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our plan to successfully grow PYLARIFY our PSMA PET franchise includes obtaining approval for and commercializing a new formulation of our F-18 PSMA PET imaging agent, conveying its our product’s commercial and clinical value, negotiating and realizing the benefits from strategic contracts with customers in the United States, expanding its use PSMA PET in appropriate new patient populations, and through strategic partnerships and collaborations, including outside of the U.S. United States.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
(in thousands) Rebates and Allowances Balance, Balance at January 1, 2023 $ 13,399 Provision related to current period revenues 32,308 Adjustments relating to prior period revenues (453) 31,855 Payments or credits made during the period (29,184) Balance, Balance at December 31, 2023 16,070 Provision related to current period revenues 63,504 Payments or credits made during the period (54,326) Balance, Balance at December 31, 2024 25,248 Provision related to current period revenues 167,628 Payments or credits made during the period (126,428) Balance at December 31, 2025 $ 25,248 66,448
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Previously, on July 3, 2024,we acquired from Life Molecular the global rights to RM2, its clinical stage RM2, a stage, gastrin-releasing peptide receptor (“GRPR”)-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, previously referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 (and which we now refer to as LNTH-2402 and LNTH-2401, respectively), for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition, and potential regulatory milestone payments plus royalties acquisition (the “RM2 Asset Purchase”). Purchase”), pursuant to the Sublicense, Development and Collaboration Agreement, by and between us and Life Molecular, dated as of June 27, 2024 (the “RM2 Sublicense Agreement”).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The primary working capital uses of cash were due to the timing of payments to large vendors, include an increase in trade receivables associated primarily with the increase timing of billings and collections and the acquisitions of Life Molecular and Evergreen in PYLARIFY revenues, and the year, an increase in inventory related to the timing of batch processes. processes and an increase in income tax receivable.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net cash used in financing activities during the year ended December 31, 2024 2025 is primarily attributable to the repurchase of our common stock for approximately $100.0 $300.0 million, the payments for minimum statutory tax withholding related to net share settlement of equity awards of $22.6 $26.3 million and the payment payments for finance leases of $2.3 million of financing costs related to the refinancing of our credit facility described below, $1.1 million, offset by proceeds of $6.7 $10.9 million from stock option exercises. exercises and issuance of common stock.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
In The 2025 Program replaced the program authorized by the Board in November 2024, our Board authorized a program 2024 to repurchase up to $250 million of our common stock during the next twelve months following the authorization (the “2024 Program”). Program”), including the remaining unused amounts under the 2024 Program.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We received an initial payment in 2023 of approximately $98.0 million in connection with the sale and have the right to receive an earned additional consideration of $5.0 million payment if worldwide net sales of RELISTOR in 2025 exceed as a specified threshold. result of the achievement of a sales-based milestone.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
We generally sell our products outside the U.S. United States through a combination of direct distribution in Canada and third party Canada, third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America and South America. America and by licensing exclusive rights to develop and commercialize certain products outside the United States.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our effective tax rate in fiscal 2024 2025 differs from the U.S. statutory rate of 21% primarily due to state income taxes and the valuation allowance established on the current year net unrealized loss on our investment in equity securities. taxes, partially offset by tax credits.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
For the year ended December 31, 2024, 2025, we recorded an unrealized losses loss on the investments investment in Radiopharm of $3.6 million and recorded an unrealized loss on the investment in Perspective of $2.6 million and $41.0 million, respectively. $5.1 million.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LNTH/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.